We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Next-Generation Sequencing Fuels Bioinformatics Upswing

By LabMedica International staff writers
Posted on 25 Nov 2013
The falling cost of genome sequencing is driving momentum to the global next-generation sequencing (NGS) bioinformatics market. More...
As cost-effective technology fuels adoption of genome sequencing in multiple end-user segments, a huge output of NGS data to store and analyze is an overwhelming result. Where primary and secondary data analysis tools are geared to become more valuable as pipelines standardize, the high-value tertiary data analysis segment used for biologic interpretation and clinical reporting will drive revenue growth, according to recent market research.

New analysis from Frost & Sullivan’s (Mountain View, CA, USA), an international growth consultancy firm, revealed that the market earned revenue of USD 170 million in 2012 and estimates this to reach USD 580 million in 2018 at a striking compound annual growth rate (CAGR) of 22.7%.

“With sequencing data production forecast to grow at a CAGR of more than 75% between 2012 and 2018, researchers will need efficient NGS informatics solutions to manage, analyze, and interpret this escalating amount of data,” said Frost & Sullivan life sciences senior industry analyst Christi Bird. “As the number of applications for NGS continues to grow, the implementation of NGS informatics will go up.”

However, customers employ NGS for a broad range of applications, and there is no perfect product for NGS informatics. Therefore, customers may have difficulty in identifying the appropriate tools for their needs. The wide variety of free public domain and commercial applications provided by more than 100 competitors in this field has also led to low barriers to entry, rising competition, and commoditization in specific product fields.

Furthermore, NGS users are frequently tentative in making further investments in commercial informatics tools, because of the range of public and open-source software available along with readily accessible internal bioinformatics resources. Therefore, in addition to the hurdles of commoditization and standardization, suppliers must persuade NGS users their commercial tools are better than free ones.

“As the market matures and informatics prices fall, competitors will rely not just on the expanding volume of users and NGS data developed but also on the high-value interpretation sector of the market to sustain profits globally,” remarked Ms. Bird. “Suppliers that can develop high-value, simple, and streamlined turnkey solutions will find success.”

Related Links:

Frost & Sullivan



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: MCD tests are designed to detect multiple cancers from a single blood sample, but the statements note that evaluating these assays is far more complex than assessing single-cancer tests (image credit: Adobe Stock)

Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests

Cancer screening is intended to reduce mortality, but policy decisions often depend on early indicators that may not fully reflect true survival benefit. The emergence of blood-based tests capable of detecting... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.